# A new class of wet AMD therapeutics

> **NIH NIH R56** · UNIVERSITY OF MISSOURI KANSAS CITY · 2022 · $391,250

## Abstract

ABSTRACT
Advanced neovascular age-related macular degeneration (AMD) is characterized by choroidal
neovascularization (CNV), in which neovessels originating from the choroid invade the macula. CNV causes
permanent central blindness if left untreated and is the most sight-threatening pathology of AMD. The present
application will investigate the efficacy and regulatory mechanisms for a new class of CNV therapeutics. Anti-
VEGF therapies are the standard of care for CNV and can preserve central vision if administered on an
indefinitely recurring basis but have reached their therapeutic threshold. Moreover, these therapies are costly
and must be injected intravitreally, increasing the risk of complications and patient noncompliance, and limiting
availability of treatment to economically disadvantaged patients affected by disparities in health care delivery.
The present application has the potential to identify new therapeutics and druggable targets for CNV,
particularly those that can be administered systemically rather than intravitreally, and are thus more accessible
to underserved populations.

## Key facts

- **NIH application ID:** 10691697
- **Project number:** 1R56EY034247-01
- **Recipient organization:** UNIVERSITY OF MISSOURI KANSAS CITY
- **Principal Investigator:** Elizabeth Pearsall
- **Activity code:** R56 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $391,250
- **Award type:** 1
- **Project period:** 2022-09-30 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10691697

## Citation

> US National Institutes of Health, RePORTER application 10691697, A new class of wet AMD therapeutics (1R56EY034247-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10691697. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*